FOXP3 and neoplasm: The pharmacological treatments available to maintain FOXP3 expression, such as CPG methylation, histone deacetylase inhibitors and the mammalian target of rapamycin (mTOR) inhibitor rapamycin (sirolimus),46 can result in general immunosuppression, which could lead to tumour relapse and infection.